About a year after Geneva-based Chord Therapeutics emerged from stealth to see if it could repurpose an old chemotherapy agent for rare diseases, Merck KGaA is swooping in with a buyout.
ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.